Document is current
Any future updates will be listed below
-
Authors
Tiel Groenestege, Erlijn
Sloothaak, Bea
van Geer-Postmus, Iris
van de Maat, Aimée
van Heijst, Ellen
van Reenen, Natascha Huijser
Kan, Kaying
Kerkhof, Marjan
Lentjes, Cindy
van der Molen, Thys
Zonneveld, Maret
in ’t Veen, Johannes
Kocks, Janwillem
-
Funding
Funding for this research was provided by:
TEVA NL (2021-052628)
Chiesi pharmaceuticals Netherlands (2020-9600)
- License Information
-
More Information
Article History
Received: 4 May 2025
Accepted: 20 September 2025
First Online: 5 January 2026
Competing interests
: IGP, AM, MK, KK and BS were employed by General Practitioners Research Institute (GPRI) at the time of the study. In the past three years (2021-2023), GPRI conducted investigator- and sponsor-initiated research funded by non-commercial organizations, academic institutes, and pharmaceutical companies (including AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, Teva, and Valneva). JK reports grants, personal fees and non-financial support from AstraZeneca, grants, personal fees and non-financial support from Boehringer Ingelheim, grants and personal fees from Chiesi Pharmaceuticals, grants, personal fees and non-financial support from GSK, personal fees and non-financial support from Mundi Pharma, grants and personal fees from TEVA, personal fees from MSD, personal fees from COVIS Pharma, grants from Valneva, outside the submitted work; JK holds <5% shares of Lothar Medtec GmbH and 72.5% of shares in the General Practitioners Research Institute. TvdM reports personal fees and non-financial support from Chiesi Pharmaceuticals, and personal fees from GSK.
